The Analysts’ Downgrades for October, 5th (BMO, CRZBY, CVX, EBS, FLR, IMGN, KSU, LLY, RST, RUSHA)

The Analysts’ Downgrades for October, 5th (BMO, CRZBY, CVX, EBS, FLR, IMGN, KSU, LLY, RST, RUSHA)

Analysts’ downgrades for Wednesday, October 5th:

Bank of Montreal (TSE:BMO) was downgraded by analysts at CSFB from a neutral rating to an underperform rating. They currently have C$93.00 price target on the stock, down from their previous price target of C$98.00.

Commerzbank AG (NASDAQ:CRZBY) was downgraded by analysts at Deutsche Bank AG from a buy rating to a hold rating. The analysts wrote, “”; sessionNotify.message = “; sessionNotify.redirect = “; (function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’); $(“document”).ready(function(){ ga(‘create’, ‘UA-57334935-1’, ‘thefly.com’); ga(‘set’, ‘dimension1’, ‘notlogged’); ga(‘send’, ‘pageview’); }); /* Wrappers para analytics */ function aTrackEvent(eventCategory, eventAction, eventLabel, eventValue, fieldsObject){ ga(‘send’, ‘event’, eventCategory, eventAction, eventLabel, eventValue, fieldsObject); log(“aTrackEvent(‘”+eventCategory+”‘,’”+eventAction+”‘,’”+eventLabel+”‘)”); return true; } {“@context”:”http://schema.org”,”@type”:”Organization”,”url”:”http://thefly.com”,”logo”:”http://thefly.com/images/logo_thefly_small.png”,”contactPoint”:[{“@type”:”ContactPoint”,”telephone”:”+1 908 273 6397″,”contactType”:”customer support”,”areaServed”:”US”,”availableLanguage”:”English”}],”sameAs”:[]} {“@context”:”http://schema.org”,”@type”:”WebSite”,”name”:”TheFly.com”,”alternateName”:”First site in stock news.”,”url”:”http://thefly.com”

10/05/analysts-downgrades-for-october-5th-bmo-crzby-cvx-ebs-flr-imgn-ksu-lly-rst-rusha.html

Commerzbank AG (NASDAQ:CRZBY) was downgraded by analysts at BNP Paribas from an outperform rating to a neutral rating.

Chevron Corp. (NYSE:CVX) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Chevron is one of the largest integrated energy firms in the world with an impressive business model. Being one of the most oil-weighted majors, Chevron is poised to benefit from the recent OPEC deal and the subsequent advancement of crude oil. As it is, the company has been able to boost returns and remain competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization. However, Chevron is still losing money from producing oil and gas, while the downstream segment is seeing its income erode on fuel oversupply and weak demand. Worse, Chevron is expected to be free-cash-flow negative this year too with profitability set to fall well short of spending. Considering these factors, we think that the current valuation is fair and adequately reflect the company's future growth prospects.”

Emergent Biosolutions (NYSE:EBS) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Emergent aims to offer specialized products to health care providers and governments to fulfil unmet medical needs and combat threats posed by serious diseases to human health. The company derives the majority of revenues from sales of its key product BioThrax to its principal purchaser, the U.S. government. Its sole dependence on BioThrax for revenues has its inherent risks and thus remains a concern. Any hiccup in the production of BioThrax could hurt the company’s top line significantly. Moreover, Emergent faces competition from a number of companies with biodefense products or candidates under development for both the U.S. government procurement and development resources. Stiff competition remains a concern as well. However, Emergent has secured a multi-year contract with the BARDA, for the advanced development and delivery of its next generation anthrax vaccine candidate, NuThrax. Its approval will be a huge boost for the company.”

Fluor Corp. (NYSE:FLR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Fluor has had a dismal earnings surprise history, with negative surprises in three of the four trailing quarters. The company’s top line growth has suffered lately, owing to reduced contribution from its Energy, Chemicals and Mining segment. Softness in commodity prices coupled with a dismal outlook for the energy and mining markets continue to pose threats to the company’s operations. The company expects slow recovery in the global economy, as customers continue to reduce capital investment budgets and delay final investment decisions, which could impact Fluor’s performance adversely. Also, Fluor faces intense competition in the global engineering, procurement and construction industry, which can pressurize its contract prices and profit margins. However, Fluor’s robust backlog level, with lucrative award wins in the Government and Infrastructure business lines, are likely to act as primary growth drivers, going forward.”

ImmunoGen (NASDAQ:IMGN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “ImmunoGen, a development-stage biotechnology company, is focused on the development of targeted anti-cancer therapeutics using its ADC technology. The company has only a limited number of wholly owned candidates in its pipeline. Moreover, most of the company’s pipeline candidates are in early stages of development, which has its risks. It will be several years before any of these candidates are even close to commercialization. In such a scenario, successful development and subsequent approval of its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer), is crucial for the company. ImmunoGen also plans to cut 17% of its workforce. The company’s heavy dependence on its partners for revenues is concerning. However, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty and other payments.”

Kansas City Southern (NYSE:KSU) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Kansas City Southern, with its wide cross-country network, remains focused on growing opportunities in cross-border intermodal businesses between the U.S. and Mexico. The company has a dominant position on the U.S.-Mexico routes. Moreover, the company’s consistent efforts to expand its business, its ability to hike prices and efforts to reduce costs continue to impress. We are also impressed by the company's efforts to reward its shareholders. However, like most railroads, the company has been adversely affected by weakness in the energy segment. The Mexican peso depreciation is another headwind. However, the company's top line is expected to improve in the second half of the year.”

Eli Lilly and (NYSE:LLY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Eli Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least two new indications/line extensions on an average every year. Products like Humalog, Trajenta, Cialis, Forteo, Strattera, Erbitux, and the animal health segment should drive growth while revenues from new products like Cyramza, Trulicity, Jardiance, Portrazza and Basaglar will pick up. However, Alimta will continue to be impacted by competition. Headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Estimates have been mostly stable ahead of the company’s Q3 earnings release. The company has a positive record of earnings surprises in recent quarters.”

Rosetta Stone (NYSE:RST) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Rosetta Stone Inc., based in Arlington, Va, is a leading provider of technology-based language learning solutions consisting of software, online services and audio practice tools, primarily under the Rosetta Stone brand. Rosetta Stone offers its self-study language learning solutions in 31 languages. Its customers include individuals, educational institutions, armed forces, government agencies and corporations. Rosetta Stone, Inc. also provides an online peer-to-peer practice environment, known as SharedTalk, at www.sharedtalk.com, where registered language learners meet for language exchange to practice their foreign language skills. As the leading language-learning software in the world, Rosetta Stone makes learning a new language second nature. Millions of learners in more than 150 countries have already used the company’s software to gain the confidence that comes with truly knowing a new language. “

Rush Enterprises (NASDAQ:RUSHA) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Rush Enterprises operates the largest network of Peterbilt heavy-duty truck dealerships in North America and John Deere construction equipment dealerships in Texas and Michigan. Their current operations include a network of dealerships located in Texas, California, Oklahoma, Louisiana, Colorado, Arizona, New Mexico and Michigan. These dealerships provide an integrated, one-stop source for the retail sale of new and used heavy-duty trucks and construction equipment; aftermarket parts, service and body shop facilities; and a wide array of financial services. “

Saia (NASDAQ:SAIA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “SCS Trans Inc is a leading transportation company that provides a variety of trucking transportation and supply chain solutions to a broad range of industries, including the retail, petrochemical and manufacturing industries. We serve a wide variety of customers by offering regional, interregional and national LTL services and selected TL services across the United States.Saia customers can choose from a wide variety of service options including overnight and second-day regional LTL shipping and a guaranteed/expedited delivery “

RetailMeNot (NASDAQ:SALE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “RetailMeNot, Inc. operates as a digital coupon marketplace that connects consumers with retailers and brands. It offers online deal information that enables users to purchase goods and services at a discount. The company’s portfolio of coupon and deal websites includes www.RetailMeNot.com, www.RetailMeNot.ca, www.VoucherCodes.co.uk, www.Deals.com, www.Actiepagina.nl, Bons-de-Reduction.com, www.ma-Reduc.com, www.Poulpeo.com and www.Deals2Buy.com. RetailMeNot, Inc. is headquartered in Austin, Texas. “

Seacoast Banking Corp. of Florida (NASDAQ:SBCF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Seacoast Banking Corp of Florida is a bank holding company. Seacoast and its subsidiaries offer a full array of deposit accounts and retail banking services, engages in consumer and commercial lending and provides a wide variety of trust and asset management services, as well as securities and annuity products. “

Silver Bay Realty Trust Corp. (NYSE:SBY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Silver Bay Realty Trust Corp. is a real estate investment trust focused on the acquisition, renovation, leasing and management of single-family properties. Silver Bay Realty Trust Corp. is based in United States. “

Related posts

Leave a Comment